RE: RBC outperform5 Apr 2024 18:24
The product seems great. However the financial projections have not been provided such as pricing information, volume of sales, next 5 year sales, margins etc. It's possible that the hospitals coming on board have been receiving free product to date to sample and decide on whether to use on an ongoing basis. That may therefore explain the negligible revenues to date?
However, it's not easy to invest in this without any projections on turnover and margins and the road to profitability.
Funding is the key issue at the moment as it will run out of money soon.
Phase 3 trials are expensive and if they can't partner with someone to fund the trials in exchange for a proportion of the future profits then they might need to shelve the trial until funding can be secured at a future date. The FDA approval process is lengthy and time consuming so possibly looking at 12-24 months from when the phase 3 trial starts. However it has much of the ROW to go after so the commercial and marketing data is essential.